Alkermes Plc

As of October 24, 2025, Alkermes Plc's technical outlook is mildly bearish, indicated by daily moving averages and monthly MACD, despite some bullish signals from the weekly MACD and Bollinger Bands.

As of October 24, 2025, Alkermes Plc's technical trend is mildly bearish, with mixed signals from various indicators including a bullish weekly MACD and mildly bearish moving averages, reflecting overall tempered sentiment.

As of October 24, 2025, Alkermes Plc's technical trend is mildly bearish, influenced by daily moving averages and Dow Theory, despite mixed signals from MACD and Bollinger Bands, and it has underperformed the S&P 500 over the past week and year-to-date.

As of October 3, 2025, Alkermes Plc's technical trend is neutral with mixed signals, showing a shift from mildly bearish to sideways, and while it has underperformed the S&P 500 over shorter periods, it has outperformed over five years, suggesting a cautious investment approach.

As of October 3, 2025, Alkermes Plc's trend is neutral with mixed indicators, outperforming the S&P 500 over the past week but lagging in longer-term returns, showing a 45.59% gain over three years compared to the S&P's 82.57%.

As of October 3, 2025, Alkermes Plc's technical trend is neutral with mixed signals, showing a sideways movement, while underperforming the S&P 500 recently but outperforming over the last three to five years.

As of September 26, 2025, Alkermes Plc shows a mildly bearish technical trend, with mixed indicators across different time frames, underperforming the S&P 500 recently but outperforming it over the longer term.

As of September 26, 2025, Alkermes Plc shows a mildly bearish technical trend with mixed indicators, having outperformed the S&P 500 in the past week but underperformed over longer periods, resulting in an overall mildly bearish stance.

As of September 26, 2025, Alkermes Plc's technical trend is mildly bearish, with mixed indicators across various timeframes, and it has underperformed the S&P 500 recently but outperformed it over the longer term.

As of September 8, 2025, Alkermes Plc's trend has shifted to mildly bearish, with mixed indicators and underperformance compared to the S&P 500 in the short term, although it has shown stronger returns over the three- and five-year periods.

As of July 7, 2025, Alkermes Plc is considered undervalued with a P/E ratio of 15 and favorable EV multiples compared to peers, despite a year-to-date return of -0.73% and a solid 3-year return of 31.42%, which lags behind the S&P 500's performance.

As of January 3, 2025, Alkermes Plc is considered undervalued with an attractive valuation grade, featuring a P/E ratio of 15, an EV to EBITDA of 10.67, and a high ROCE of 61.70%, while trading at a discount compared to peers like United Therapeutics and outperforming the S&P 500 over the past year.

As of June 13, 2025, Alkermes Plc shows a mildly bearish trend due to bearish weekly MACD and KST indicators, despite some bullish signals in the monthly timeframe.

As of March 2022, the management team of Alkermes Plc includes CEO Richard Pops, Lead Independent Director David Anstice, and independent directors Shane Cooke, Robert Breyer, David Daglio, and Wendy Dixon.

Alkermes Plc is a mid-cap biopharmaceutical company focused on researching, developing, and commercializing pharmaceutical products. As of March 2025, it reported net sales of $307 million and a net profit of $22 million.